Phosphorus-containing compound, pharmaceutical composition thereof and use thereof

By providing a new phosphorus-containing compound and its pharmaceutical composition, the problem of limited types of kinase inhibitors in the prior art is solved, effective inhibition of MAP4K3 and HPK1 is achieved, and new therapeutic options are provided for cancer and itself Immune diseases.

WO2025000675A1PCT designated stage expired Publication Date: 2025-01-02LYNK PHARMACEUTICALS CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/115072
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-29
Filing Date
2023-08-25
Publication Date
2025-01-02

AI Technical Summary

Technical Problem

In the prior art, there are limited types of kinase inhibitors, and it is difficult to effectively inhibit MAP4K3 and HPK1 kinases, resulting in insufficient in tumor immunotherapy and autoimmune disease treatment.

Method used

A new phosphorus-containing compound and its pharmaceutical composition are provided. By preparing HPK1 inhibitors and MAP4K3 inhibitors, it is used to treat cancer and autoimmune diseases. The compound has a good inhibitory activity against MAP4K3 or HPK1.

Benefits of technology

The compounds have significant inhibitory activities on MAP4K3 or HPK1 and can be effectively used to prepare drugs that are anti-tumor and anti-autoimmune diseases, providing new therapeutic options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023115072_02012025_PF_FP_ABST
    Figure CN2023115072_02012025_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are a phosphorus-containing compound, a pharmaceutical composition thereof and a use thereof. Specifically, disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof. The phosphorus-containing compound of the present invention has relatively good inhibitory activity against MAP4K3 or HPK1 kinase.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Benzopyrimidine and benzotriazine hematopoietic progenitor cell kinase 1 degradation agent and application thereof

    CN115873018A

  • Kinase Inhibitor Phosphonate Conjugates

    US20070281907A1

  • Map kinase kinase kinase kinase 3 (map4k3) as a biomarker and therapetic target for autoimmune disease, cancer, inflammation and il-17-associated disease

    US20130017550A1

  • HPK1 inhibitors and uses thereof

    WO2021000935A1

  • Alkyne compound as HPK1 inhibitor and use thereof

    WO2022228522A1